Private Wealth Partners LLC Grows Position in Novo Nordisk A/S (NYSE:NVO)

Private Wealth Partners LLC grew its position in Novo Nordisk A/S (NYSE:NVO - Free Report) by 155.1% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 33,203 shares of the company's stock after acquiring an additional 20,188 shares during the period. Private Wealth Partners LLC's holdings in Novo Nordisk A/S were worth $3,953,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Price T Rowe Associates Inc. MD grew its stake in Novo Nordisk A/S by 10.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,589,222 shares of the company's stock valued at $1,102,857,000 after acquiring an additional 823,036 shares in the last quarter. Envestnet Asset Management Inc. lifted its holdings in shares of Novo Nordisk A/S by 1.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company's stock worth $607,242,000 after acquiring an additional 58,935 shares during the last quarter. GQG Partners LLC lifted its holdings in Novo Nordisk A/S by 654.6% during the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company's stock worth $466,485,000 after buying an additional 3,151,584 shares in the last quarter. Raymond James & Associates lifted its holdings in Novo Nordisk A/S by 1.0% during the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company's stock worth $419,939,000 after buying an additional 36,223 shares in the last quarter. Finally, 1832 Asset Management L.P. lifted its holdings in Novo Nordisk A/S by 7.8% during the 1st quarter. 1832 Asset Management L.P. now owns 2,373,029 shares of the company's stock worth $304,697,000 after buying an additional 172,003 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on NVO shares. Cantor Fitzgerald restated an "overweight" rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, October 10th. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a report on Friday. Finally, BMO Capital Markets reduced their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of "Buy" and a consensus price target of $144.50.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock traded down $0.01 during midday trading on Friday, hitting $111.94. 4,554,729 shares of the company's stock were exchanged, compared to its average volume of 4,701,665. Novo Nordisk A/S has a 12-month low of $94.73 and a 12-month high of $148.15. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.75 and a current ratio of 0.94. The stock has a market cap of $502.33 billion, a price-to-earnings ratio of 38.34, a price-to-earnings-growth ratio of 1.46 and a beta of 0.43. The firm's 50 day simple moving average is $124.25 and its 200 day simple moving average is $130.94.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, August 7th. The company reported $0.65 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.71 by ($0.06). Novo Nordisk A/S had a return on equity of 87.43% and a net margin of 34.86%. The business had revenue of $9.82 billion for the quarter, compared to analysts' expectations of $9.91 billion. Equities research analysts predict that Novo Nordisk A/S will post 3.01 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a semi-annual dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 16th were issued a $0.5126 dividend. This represents a dividend yield of 0.7%. The ex-dividend date was Friday, August 16th. Novo Nordisk A/S's payout ratio is 24.66%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.